What are the common immune markers in ankylosing spondylitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Immune Markers in Ankylosing Spondylitis

The most clinically relevant immune markers in ankylosing spondylitis are HLA-B27 (positive in 74-89% of patients), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), though none of these should be used alone to rule out the disease. 1

HLA-B27: The Primary Genetic Marker

HLA-B27 is the strongest immune marker associated with ankylosing spondylitis, present in 74% to 89% of patients with axial spondyloarthritis. 1 However, this marker must be interpreted carefully:

  • HLA-B27 should function as a screening parameter rather than a definitive diagnostic test, with only 30-40% of patients with chronic back pain and positive HLA-B27 ultimately receiving an AS diagnosis. 2, 3

  • Approximately 10% of AS cases are HLA-B27 negative, meaning a negative test cannot exclude the diagnosis. 3

  • The test only needs to be performed once in a patient's lifetime using molecular methods that detect the HLA-B27 genotype directly. 3

  • HLA-B27 positivity increases the likelihood of peripheral spondyloarthritis, but should be combined with clinical criteria for referral decisions. 1, 2

Inflammatory Markers: CRP and ESR

C-reactive protein and erythrocyte sedimentation rate are the standard inflammatory markers monitored in AS, though they have significant limitations:

  • Spondyloarthritis should NOT be ruled out based solely on normal CRP or ESR values, as these can be normal even in active disease. 1

  • CRP and ESR should be monitored regularly alongside validated AS disease activity measures to assess treatment response and disease progression. 1

  • These markers provide additional information when combined with MRI findings for monitoring disease activity in axial spondyloarthritis. 1

Critical Clinical Pitfall

The single most important pitfall is ruling out spondyloarthritis based on negative laboratory results alone. 1 The diagnosis cannot be excluded based on:

  • Negative HLA-B27 testing
  • Normal C-reactive protein levels
  • Normal erythrocyte sedimentation rate

All three markers must be interpreted within the clinical context of inflammatory back pain characteristics, imaging findings, and extra-articular manifestations. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Role of HLA-B27 Testing in Ankylosing Spondylitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

HLA-B27 Testing for Ankylosing Spondylitis Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.